Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies
Open Access

Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery

KATSUHISA HIRANO, ISAYA HASHIMOTO, NANA KIMURA, MINA FUKASAWA, RYO MURANUSHI, YOSHIHIRO SHIRAI, TORU WATANABE, KAZUTO SHIBUYA, ISAKU YOSHIOKA and TSUTOMU FUJII
Anticancer Research June 2025, 45 (6) 2467-2476; DOI: https://doi.org/10.21873/anticanres.17618
KATSUHISA HIRANO
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ISAYA HASHIMOTO
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NANA KIMURA
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MINA FUKASAWA
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYO MURANUSHI
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO SHIRAI
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TORU WATANABE
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUTO SHIBUYA
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ISAKU YOSHIOKA
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUTOMU FUJII
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fjt@med.u-toyama.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Gastric outlet obstruction (GOO) is common in patients with advanced pancreatic cancer. Previous reports have documented the efficacy of gastrojejunostomy (GJ) bypass and endoscopic procedures. However, the optimal timing for GJ bypass remains unclear. This study aimed to determine the optimal timing for GJ bypass in pancreatic cancer.

Patients and Methods: This study included patients who underwent GJ bypass for GOO with pancreatic cancer at our institute between 2009 and 2023. Asymptomatic GOO was defined as gastroduodenal transit disturbance on imaging studies but without severe symptoms. Patients were divided into early and late groups based on the day of oral intake resumption.

Results: The study included 65 patients. The median time to resume postoperative oral intake was four days. According to the median value, 38 and 27 patients were assigned to the early and late recovery groups, respectively. Peritoneal dissemination was more common in the late-stage group (p=0.05). Asymptomatic GOO, laparoscopic surgery, and linear stapler use were significantly more common in the early recovery group. Multivariate analysis showed that symptomatic GOO was an independent variable for late recovery (odds ratio=12.7; p=0.0006; 95% confidence interval=2.7-95.1).

Conclusion: Early surgical intervention with GJ is recommended when asymptomatic GOO is suggested by imaging. This approach may facilitate earlier postoperative recovery and support continuity in multidisciplinary treatment strategies for pancreatic cancer.

Keywords:
  • Gastrojejunostomy
  • palliative surgery
  • gastric outlet obstruction
  • asymptomatic gastric outlet obstruction
  • pancreatic cancer

Introduction

Malignancies of the pancreas, biliary tract, and gastroduodenum are often diagnosed in the advanced stages, or may grow without responding to chemotherapy or chemoradiation. Malignant gastric outlet obstruction (GOO) is a symptom caused by various tumors, including those of the pancreas, biliary tract, and gastroduodenum, and is defined as mechanical obstruction of the pylorus or duodenum secondary to compression or infiltration from these malignancies. Consequently, oral intake is often difficult or impossible to achieve (1). Patients with malignant GOO present with persistent nausea, vomiting, anorexia, abdominal pain, weight loss, malnutrition, and dehydration. GOO worsens the patient’s general condition, forcing the patient to discontinue systemic chemotherapy and preventing the improvement of the general condition.

The two main treatments for GOO are surgery and endoscopy. Previous reports have shown that the surgical approach has the advantage of longer relief of symptoms and less need for reintervention. In contrast, the endoscopic approach has shown that enteral stents using self-expanding metal stents rapidly improve enteral dysfunction with minimal invasion. However, enteral stents have also shown a high dysfunction rate owing to tumor growth and a higher rate of reintervention.

Recently, endoscopic ultrasound-guided gastroenterostomy (EUS-GE) has been reported as a novel technique for managing malignant GOO (2, 3). While previous studies have discussed the advantages and disadvantages of various treatment approaches for GOO (4), the optimal timing of intervention remains unclear. In this study, we retrospectively evaluated gastrojejunostomy (GJ) bypass for GOO due to pancreatic cancer (PC) and aimed to determine the optimal timing for GJ bypass.

Patients and Methods

Patients and study design. We searched a database maintained postoperatively at our institute between April 2009 and December 2023. Patients who underwent surgical GJ bypass for GOO due to PC were included in this study. This study was approved by the Institutional Review Board (R2022148).

Patients with PC and persistent nausea or vomiting due to gastric or duodenal strictures were defined as having symptomatic GOO. In contrast, patients with not persistent nausea or vomiting but with stenosis of the stomach or duodenum invasion or compression by the PC revealed by computed tomography (CT) or other imaging studies were diagnosed with asymptomatic GOO. Oral intake was graded using the GOO Scoring System (GOOSS) (0=no intake, 1=liquid only, 2=soft solids, 3=almost full diet, and 4=full diet) (5). Symptomatic GOO was defined as a GOOSS score of 0, or persistent nausea, vomiting, or anorexia not related to chemotherapy or other treatment. Clinical success was defined as the ability to tolerate at least a liquid diet after GJ bypass without symptoms due to GOO (GOOSS: ≥2) (6). To evaluate the optimal timing of GJ bypass, the patients were divided into two groups. Patients who were able to resume oral intake earlier after GJ bypass and who achieved clinical success were included in the early group. The remaining patients were assigned to the late recovery group. The threshold for classifying the patients into two groups was the median number of days that the patients were able to resume oral intake after GJ bypass. The exclusion criteria were as follows: (i) severe peritoneal dissemination or cancerous peritonitis, (ii) history of upper abdominal surgery, (iii) recurrence of PC after curative resection, and (iv) missing medical records.

Surgical procedures. Laparoscopic surgery is usually performed for GJ bypass. Patients who underwent upper gastrointestinal tract surgery were selected for open GJ. In cases of severe intra-abdominal adhesions or PC invasion, continuing laparoscopic surgery was difficult, and the patient underwent open surgery.

Laparoscopic GJ bypass. Patients were placed in a supine position with their legs apart. Five trocars were used in the study. The first 12 mm trocar for laparoscopy was inserted through a small umbilical incision. Carbon dioxide pneumoperitoneum was established, and the remaining four trocars were placed in the upper abdomen. After all the trocars were in place, the abdominal cavity was carefully observed to detect peritoneal dissemination or liver metastasis. Peritoneal lavage cytology was performed.

After dissection of the greater omentum, the posterior wall of the stomach was exposed, and no direct invasion of the PC was confirmed. A small hole was created on the mesenteric side of the jejunum. A small hole was also made in the posterior wall of the gastric antrum, close to the greater curvature. The limb of the 60 mm linear stapler was inserted into the jejunum. The jejunum was elevated via the antecolic route, the other limb was inserted into the stomach, and GJ was performed. GJ was routinely performed on the posterior wall of the greater curvature of the stomach. The common hole was closed using absorbable sutures. Jejunojejunal side-to-side anastomosis was performed with a 45 mm linear stapler using a procedure similar to that used for GJ. In patients with confirmed PC invasion of the posterior stomach wall, GJ was performed on the anterior wall of the stomach. In patients who underwent hand suturing, the procedure of anastomosis and selection of the anastomotic position were the same as those using linear staplers.

Data collection. We evaluated the clinical features, intraoperative and postoperative findings, and treatment after GJ. Blood examinations were performed, including preoperative nutritional status, total protein, albumin, cholinesterase, total cholesterol (T-Cho), and lymphocyte count. The Controlling Nutritional Status (CONUT) score, which is calculated using serum albumin, the number of lymphocytes, T-Cho, and the Prognostic Nutritional Index (PNI), which is calculated as follows: 10 × serum albumin (g/dl) + 0.005 × lymphocyte count (per mm3), was used to evaluate the preoperative nutritional status (7, 8). PC resectability was diagnosed based on the National Comprehensive Cancer Network Guidelines Version 2.2021 (9). Postoperative complications were defined as grades III-V according to the Clavien–Dindo classification (10).

Statistical analysis. Differences in the nominal dates between the two groups were examined using the chi-square test. Differences in quantitative variables were evaluated using the Mann–Whitney U-test. Logistic regression analysis was used for multivariate analysis. Statistical significance was set at p<0.05. All statistical analyses were performed using JMP software (version 15.0; SAS Institute, Cary, NC, USA).

Results

Sixty-nine patients underwent GJ for GOO and PC. Four patients were excluded for the following reasons: one had multiple small bowel obstructions due to peritoneal dissemination and three had recurrence after pancreatoduodenectomy (Figure 1). The remaining 65 patients were included in this study. Patient backgrounds are shown in Table I. The most common tumor location was the pancreatic head (69.2%). Fifty-five patients were diagnosed with unresectable PC, however, two patients were diagnosed with resectable PC and underwent radical resection after GJ bypass and subsequent neoadjuvant chemotherapy. Of 42 patients diagnosed with unresectable metastatic (UR-M) pancreatic cancer, 25 had confirmed peritoneal dissemination. Among all patients, 36 (55.4%) were diagnosed as positive by peritoneal lavage cytology. Sixty patients (92.3%) had duodenal outlet obstruction. Twenty patients (33.3%) had stenosis of the first or second portion of the duodenum, and 40 patients (66.7%) had stenosis of the third or fourth portion of the duodenum. Forty-two patients (64.6%) were diagnosed with symptomatic GOO and treated conservatively for 17 (1-102) days before undergoing GJ bypass. The operative findings are summarized in Table II. Thirty-seven patients underwent laparoscopic GJ bypass, and five underwent choledochojejunostomy at the same time. Forty-two patients (64.6%) underwent GJ with a linear stapler. The patients resumed oral intake on postoperative day (POD) 4 (2-13). The clinical success rate of the resumption of oral intake was 85.7%. Twenty-two patients were selected for best supportive care after GJ bypass. The remaining 41 patients received chemotherapy on POD 19 (6-69). Chemotherapy was resumed on POD 20 (4-113) (Table III).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Patient flowchart. Three patients were diagnosed with gastric outlet obstruction (GOO) after curative resection of pancreatic cancer, and one patient was diagnosed with multiple bowel obstructions due to peritoneal dissemination.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Characteristics of patients.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Operative findings.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Postoperative findings.

To evaluate the optimal timing of GJ bypass for GOO with PC, patients were classified into two groups based on the median POD value at which they started oral intake. Patients who started oral intake within four days after surgery were classified into the early recovery group, and those who started oral intake after POD5 were classified into the late recovery group. The early recovery group included 37 patients, whereas the late recovery group included 26 patients. There were no significant differences in patient backgrounds (Table IV). Peritoneal dissemination was more common in the late recovery group than in the early recovery group (p=0.05). Twenty-four patients in the late recovery group were diagnosed with symptomatic GOO (88.9%), 18 in the early recovery group were diagnosed with symptomatic GOO (48.6%), and significantly more patients were diagnosed in the late recovery group (p=0.003). Regarding intraoperative features, the early recovery group had significantly more laparoscopic surgeries, less blood loss, and more anastomoses using a linear stapler (Table V). However, there were no significant differences in the diameter of the anastomosis or anastomotic location in the stomach between the two groups (Table VI). Twelve patients (32.4%) in the early recovery group and 10 (38.4%) in the late recovery group chose the best supportive care after GJ bypass (p=0.62). Two of 25 patients in the early recovery group who received chemotherapy after GJ bypass underwent curative pancreatectomy.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Comparison of patients’ background.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Comparison of operative and postoperative findings.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VI.

Multivariable analyses of the factors that late postoperative oral intake.

In the early recovery group, patients experienced the first postoperative flatus significantly earlier, resumed water intake and oral feeding earlier, and had a significantly shorter postoperative hospital stay. The clinical success rate of oral intake was significantly higher in the early recovery group (35 patients, 94.5%) than in the late recovery group (seven patients, 26.9%). However, there were no significant differences in the duration of chemotherapy interruption (days) or resumption of chemotherapy after GJ bypass (POD) between the two groups (Table V).

Variables that were determined preoperatively to have a p-value less than 0.05 were included in a subsequent multivariate analysis to identify the risk factors for late postoperative recovery. In multivariate analysis, only symptomatic GOO was selected as an independent factor for late recovery [odds ratio=12.7; p=0.0006; 95% confidence interval (CI)=2.7-95.1] (Table IV).

Discussion

GOO is a common clinical condition resulting from locally advanced malignant tumors adjacent to the stomach or duodenum, such as gastric, duodenal, or PCs. GOO often develops in highly advanced PC, and its treatment is palliative. Palliative therapies for GOO are divided into two main categories: endoscopic and surgical. Self-expanding metal stents (SEMS) have been selected for endoscopic procedures since the late 1990s (11, 12). Recently, EUS-GE with the placement of a lumen-apposing metal stent has become an increasingly adopted approach (2, 6, 13-17). GJ with laparotomy or a laparoscopic approach is often used in surgical procedures. Previous studies, including systematic reviews, have often focused on procedures that are more effective for GOO (1, 4, 6, 18-21). Compared with surgical GJ bypass, SEMS tended to improve symptoms of GOO faster and have shorter life due to tumor growth. GJ bypass was performed in patients with a life expectancy of ≥2 months because of a longer term patency could be expected (17). However, EUS-GE was reported to have equivalent clinical success and reintervention rates but significantly fewer adverse events than surgical GJ bypass.

However, to the best of our knowledge, there are no reports on the optimal timing of therapeutic interventions for GOO. In our study, the clinical success rate of GJ bypass for GOO in patients with PC was 85.7%. In the early recovery group, clinical success rate was 94.5%. Patients who were able to resume postoperative oral intake also had a higher clinical success rate for GJ bypass. Therefore, evaluating the factors that allow earlier resumption of postoperative oral intake is important to validate the optimal timing of GJ bypass for GOO with PC. The patients were classified into early and late recovery groups. There was a trend toward more cases of peritoneal dissemination in the late recovery group; however, there was no significant difference between the two groups. This suggests that peritoneal dissemination is not a reason for avoiding GJ bypass for GOO in PC. In cases of peritoneal dissemination, the indications for GJ bypass should be comprehensively judged based on peritoneal dissemination, PC progression, and general condition. The GJ bypass procedure showed no significant difference in operative time between laparoscopic and open surgery, with significantly less blood loss during laparoscopic surgery (data not shown). Laparoscopic surgery is the first choice for GJ bypass.

Patients with a PNI ≤40 have contraindications for intestinal anastomosis (8). No postoperative leakage was observed in any of the patients. In GOO patients with PC, owing to the continuation of chemotherapy, pancreatic exocrine insufficiency, decreased oral intake, and other factors, their nutritional status was considered inadequate. Our study suggests that surgery should be performed as early as possible if the patient’s general condition permits without adherence to preoperative nutritional management, using PNI and CONUT as indicators.

In this study, univariate analysis showed significant differences in symptomatic GOO, laparoscopic surgery, and GJ bypass with a linear stapler. However, there were no significant differences in peritoneal lavage cytology or peritoneal dissemination. These facts suggest that the presence of peritoneal lavage cytology or peritoneal dissemination alone is not a reason to avoid GJ bypass in GOO with PC. In the multivariate analysis, only preoperative symptomatic GOO was identified as a factor that delayed resumption of oral intake after GJ bypass. Preoperative CT revealed duodenal edema and a dilated stomach or duodenum in almost all patients; however, no findings that could predict the development of symptomatic GOO were found in this study.

Of the patients who underwent GJ bypass, chemotherapy was administered to 63%, and conversion surgery was performed in two patients in the early recovery group. Thus, GJ bypass for GOO in PC was not only a palliative treatment in the terminal state, but an essential component of multidisciplinary treatment. Multidisciplinary treatment is important for improving the prognosis of PC (22-27). Therefore, continuous treatment is necessary. In the present study, there were no significant differences in the duration of chemotherapy interruption or time to chemotherapy resumption after GJ bypass between the early and late recovery groups. This may be because the patients’ backgrounds were inconsistent.

Study limitations. First, it was a retrospective study with a small sample size. Second, the lack of comparison with endoscopic procedures limits evaluation of the optimal procedure for GOO in PC. Third, patients with severe cancerous peritonitis with massive ascites effusion or severe peritoneal dissemination were excluded. This may have resulted in selection bias.

Conclusion

Asymptomatic GOO is an independent factor that delays the resumption of oral intake after GJ bypass. Early surgical intervention is recommended if GOO is suggested on CT or other imaging studies. Moreover, GJ bypass is not only a palliative treatment for PC but also an aggressive option as part of the multidisciplinary treatment for advanced PC.

Footnotes

  • Authors’ Contributions

    K.H. and I.H. contributed to data collection. K.H. analyzed the data and wrote the manuscript, the figure and the tables. T.F. supervised all activities. All Authors have read and approved the published version of the manuscript.

  • Conflicts of Interest

    The Authors confirm there are no conflicts of interest in relation to this study.

  • Artificial Intelligence (AI) Disclosure

    No artificial intelligence (AI) tools, including large language models or machine learning software, were used in the preparation, analysis, or presentation of this manuscript.

  • Received April 8, 2025.
  • Revision received April 16, 2025.
  • Accepted April 17, 2025.
  • Copyright © 2025 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Troncone E,
    2. Fugazza A,
    3. Cappello A,
    4. Del Vecchio Blanco G,
    5. Monteleone G,
    6. Repici A,
    7. Teoh AYB,
    8. Anderloni A
    : Malignant gastric outlet obstruction: Which is the best therapeutic option? World J Gastroenterol 26(16): 1847-1860, 2020. DOI: 10.3748/wjg.v26.i16.1847
    OpenUrlCrossRefPubMed
  2. ↵
    1. Tyberg A,
    2. Perez-Miranda M,
    3. Sanchez-Ocaña R,
    4. Peñas I,
    5. de la Serna C,
    6. Shah J,
    7. Binmoeller K,
    8. Gaidhane M,
    9. Grimm I,
    10. Baron T,
    11. Kahaleh M
    : Endoscopic ultrasound-guided gastrojejunostomy with a lumen-apposing metal stent: a multicenter, international experience. Endosc Int Open 4(3): E276-E281, 2016. DOI: 10.1055/s-0042-101789
    OpenUrlCrossRefPubMed
  3. ↵
    1. Barthet M,
    2. Binmoeller KF,
    3. Vanbiervliet G,
    4. Gonzalez JM,
    5. Baron TH,
    6. Berdah S
    : Natural orifice transluminal endoscopic surgery gastroenterostomy with a biflanged lumen-apposing stent: first clinical experience (with videos). Gastrointest Endosc 81(1): 215-218, 2015. DOI: 10.1016/j.gie.2014.09.039
    OpenUrlCrossRefPubMed
  4. ↵
    1. Papanikolaou IS,
    2. Siersema PD
    : Gastric outlet obstruction: current status and future directions. Gut Liver 16(5): 667-675, 2022. DOI: 10.5009/gnl210327
    OpenUrlCrossRefPubMed
  5. ↵
    1. Adler DG,
    2. Baron TH
    : Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients. Am J Gastroenterol 97(1): 72-78, 2002. DOI: 10.1111/j.1572-0241.2002.05423.x
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bomman S,
    2. Ghafoor A,
    3. Sanders DJ,
    4. Jayaraj M,
    5. Chandra S,
    6. Krishnamoorthi R
    : Endoscopic ultrasound-guided gastroenterostomy versus surgical gastrojejunostomy in treatment of malignant gastric outlet obstruction: Systematic review and meta-analysis. Endosc Int Open 10(4): E361-E368, 2022. DOI: 10.1055/a-1783-8949
    OpenUrlCrossRefPubMed
  7. ↵
    1. de Ulíbarri Pérez JI,
    2. Fernández G,
    3. Rodríguez Salvanés F,
    4. Díaz López AM
    : Nutritional screening; control of clinical undernutrition with analytical parameters. Nutr Hosp 29(4): 797-811, 2014. DOI: 10.3305/nh.2014.29.4.7275
    OpenUrlCrossRefPubMed
  8. ↵
    1. Onodera T,
    2. Goseki N,
    3. Kosaki G
    : [Prognostic Nutritional Index in gastrointestinal surgery of malnourished cancer patients]. Nippon Geka Gakkai Zasshi 85(9): 1001-1005, 1982.
    OpenUrl
  9. ↵
    1. Tempero MA,
    2. Malafa MP,
    3. Al-Hawary M,
    4. Behrman SW,
    5. Benson AB,
    6. Cardin DB,
    7. Chiorean EG,
    8. Chung V,
    9. Czito B,
    10. Del Chiaro M,
    11. Dillhoff M,
    12. Donahue TR,
    13. Dotan E,
    14. Ferrone CR,
    15. Fountzilas C,
    16. Hardacre J,
    17. Hawkins WG,
    18. Klute K,
    19. Ko AH,
    20. Kunstman JW,
    21. LoConte N,
    22. Lowy AM,
    23. Moravek C,
    24. Nakakura EK,
    25. Narang AK,
    26. Obando J,
    27. Polanco PM,
    28. Reddy S,
    29. Reyngold M,
    30. Scaife C,
    31. Shen J,
    32. Vollmer C,
    33. Wolff RA,
    34. Wolpin BM,
    35. Lynn B,
    36. George GV
    : Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(4): 439-457, 2021. DOI: 10.6004/jnccn.2021.0017
    OpenUrlCrossRefPubMed
  10. ↵
    1. Dindo D,
    2. Demartines N,
    3. Clavien PA
    : Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2): 205-213, 2004. DOI: 10.1097/01.sla.0000133083.54934.ae
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kozarek RA,
    2. Ball TJ,
    3. Patterson DJ
    : Metallic self-expanding stent application in the upper gastrointestinal tract: caveats and concerns. Gastrointest Endosc 38(1): 1-6, 1992. DOI: 10.1016/s0016-5107(92)70321-6
    OpenUrlCrossRefPubMed
  12. ↵
    1. Topazian M,
    2. Ring E,
    3. Grendell J
    : Palliation of obstructing gastric cancer with steel mesh, self-expanding endoprostheses. Gastrointest Endosc 38(1): 58-60, 1992. DOI: 10.1016/s0016-5107(92)70334-4
    OpenUrlCrossRefPubMed
  13. ↵
    1. Khashab MA,
    2. Baron TH,
    3. Binmoeller KF,
    4. Itoi T
    : EUS-guided gastroenterostomy: a new promising technique in evolution. Gastrointest Endosc 81(5): 1234-1236, 2015. DOI: 10.1016/j.gie.2014.12.053
    OpenUrlCrossRefPubMed
    1. Carbajo AY,
    2. Kahaleh M,
    3. Tyberg A
    : Clinical review of EUS-guided gastroenterostomy (EUS-GE). J Clin Gastroenterol 54(1): 1-7, 2020. DOI: 10.1097/MCG.0000000000001262
    OpenUrlCrossRef
    1. Irani S,
    2. Baron TH,
    3. Itoi T,
    4. Khashab MA
    : Endoscopic gastroenterostomy: techniques and review. Curr Opin Gastroenterol 33(5): 320-329, 2017. DOI: 10.1097/MOG.0000000000000389
    OpenUrlCrossRefPubMed
    1. Itoi T,
    2. Ishii K,
    3. Ikeuchi N,
    4. Sofuni A,
    5. Gotoda T,
    6. Moriyasu F,
    7. Dhir V,
    8. Teoh AYB,
    9. Binmoeller KF
    : Prospective evaluation of endoscopic ultrasonography-guided double-balloon-occluded gastrojejunostomy bypass (EPASS) for malignant gastric outlet obstruction. Gut 65(2): 193-195, 2016. DOI: 10.1136/gutjnl-2015-310348
    OpenUrlFREE Full Text
  14. ↵
    1. Khashab MA,
    2. Kumbhari V,
    3. Grimm IS,
    4. Ngamruengphong S,
    5. Aguila G,
    6. El Zein M,
    7. Kalloo AN,
    8. Baron TH
    : EUS-guided gastroenterostomy: the first U.S. clinical experience (with video). Gastrointest Endosc 82(5): 932-938, 2015. DOI: 10.1016/j.gie.2015.06.017
    OpenUrlCrossRefPubMed
  15. ↵
    1. Jeong SJ,
    2. Lee J
    : Management of gastric outlet obstruction: Focusing on endoscopic approach. World J Gastrointest Pharmacol Ther 11(2): 8-16, 2020. DOI: 10.4292/wjgpt.v11.i2.8
    OpenUrlCrossRefPubMed
    1. Jain H,
    2. Dey D,
    3. Odat RM,
    4. Hussein AM,
    5. Abbasi HQ,
    6. Madaan H,
    7. Goyal A,
    8. Jain J,
    9. Ahmed M,
    10. Marsool MDM,
    11. Yadav R
    : Endoscopic ultrasound-guided gastroenterostomy versus duodenal stenting for gastric outlet obstruction: A systematic review, meta-analysis, and meta-regression. Medicine (Baltimore) 103(40): e39948, 2024. DOI: 10.1097/MD.0000000000039948
    OpenUrlCrossRefPubMed
    1. Krishnamoorthi R,
    2. Bomman S,
    3. Benias P,
    4. Kozarek RA,
    5. Peetermans JA,
    6. McMullen E,
    7. Gjata O,
    8. Irani SS
    : Efficacy and safety of endoscopic duodenal stent versus endoscopic or surgical gastrojejunostomy to treat malignant gastric outlet obstruction: systematic review and meta-analysis. Endosc Int Open 10(6): E874-E897, 2022. DOI: 10.1055/a-1794-0635
    OpenUrlCrossRefPubMed
  16. ↵
    1. Teoh AYB,
    2. Lakhtakia S,
    3. Tarantino I,
    4. Perez-Miranda M,
    5. Kunda R,
    6. Maluf-Filho F,
    7. Dhir V,
    8. Basha J,
    9. Chan SM,
    10. Ligresti D,
    11. Ma MTW,
    12. de la Serna-Higuera C,
    13. Yip HC,
    14. Ng EKW,
    15. Chiu PWY,
    16. Itoi T
    : Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial. Hepatol 9(2): 124-132, 2024. DOI: 10.1016/S2468-1253(23)00242-X
    OpenUrlCrossRef
  17. ↵
    1. Igarashi T,
    2. Yamada S,
    3. Hoshino Y,
    4. Murotani K,
    5. Baba H,
    6. Takami H,
    7. Yoshioka I,
    8. Shibuya K,
    9. Kodera Y,
    10. Fujii T
    : Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study. Ann Gastroenterol Surg 7(1): 157-166, 2022. DOI: 10.1002/ags3.12613
    OpenUrlCrossRefPubMed
    1. Matsumura M,
    2. Honda G,
    3. Tani K,
    4. Nemoto S,
    5. Ome Y,
    6. Hayakawa S,
    7. Suzuki M,
    8. Horiguchi SI,
    9. Kikuyama M,
    10. Seyama Y
    : The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 7(2): 306-317, 2022. DOI: 10.1002/ags3.12624
    OpenUrlCrossRefPubMed
    1. Kondo N,
    2. Uemura K,
    3. Sumiyoshi T,
    4. Okada K,
    5. Seo S,
    6. Otsuka H,
    7. Kawano R,
    8. Murakami Y,
    9. Takahashi S
    : Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using inverse probability of treatment weighting. J Hepatobiliary Pancreat Sci 29(8): 911-921, 2022. DOI: 10.1002/jhbp.1151
    OpenUrlCrossRefPubMed
    1. Kim HS,
    2. Lee M,
    3. Han Y,
    4. Kang JS,
    5. Kang YH,
    6. Sohn HJ,
    7. Kwon W,
    8. Lee DH,
    9. Jang JY
    : Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels. J Hepatobiliary Pancreat Sci 30(7): 924-934, 2023. DOI: 10.1002/jhbp.1302
    OpenUrlCrossRefPubMed
    1. Ishida M,
    2. Fujii T,
    3. Kishiwada M,
    4. Shibuya K,
    5. Satoi S,
    6. Ueno M,
    7. Nakata K,
    8. Takano S,
    9. Uchida K,
    10. Ohike N,
    11. Masugi Y,
    12. Furukawa T,
    13. Hirabayashi K,
    14. Fukushima N,
    15. Yi SQ,
    16. Isayama H,
    17. Itoi T,
    18. Ohtsuka T,
    19. Okusaka T,
    20. Inoue D,
    21. Kitagawa H,
    22. Takaori K,
    23. Tani M,
    24. Nagakawa Y,
    25. Yoshitomi H,
    26. Unno M,
    27. Takeyama Y
    : Japanese classification of pancreatic carcinoma by the Japan Pancreas Society: Eighth edition. J Hepatobiliary Pancreat Sci 31(11): 755-768, 2024. DOI: 10.1002/jhbp.12056
    OpenUrlCrossRefPubMed
  18. ↵
    1. Fukasawa M,
    2. Watanabe T,
    3. Tanaka H,
    4. Itoh A,
    5. Kimura N,
    6. Shibuya K,
    7. Yoshioka I,
    8. Murotani K,
    9. Hirabayashi K,
    10. Fujii T
    : Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology. J Hepatobiliary Pancreat Sci 30(11): 1261-1272, 2023. DOI: 10.1002/jhbp.1356
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 45 (6)
Anticancer Research
Vol. 45, Issue 6
June 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery
KATSUHISA HIRANO, ISAYA HASHIMOTO, NANA KIMURA, MINA FUKASAWA, RYO MURANUSHI, YOSHIHIRO SHIRAI, TORU WATANABE, KAZUTO SHIBUYA, ISAKU YOSHIOKA, TSUTOMU FUJII
Anticancer Research Jun 2025, 45 (6) 2467-2476; DOI: 10.21873/anticanres.17618

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery
KATSUHISA HIRANO, ISAYA HASHIMOTO, NANA KIMURA, MINA FUKASAWA, RYO MURANUSHI, YOSHIHIRO SHIRAI, TORU WATANABE, KAZUTO SHIBUYA, ISAKU YOSHIOKA, TSUTOMU FUJII
Anticancer Research Jun 2025, 45 (6) 2467-2476; DOI: 10.21873/anticanres.17618
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer
  • Pathologic Complete Response (pCR) in Patient With Myxofibrosarcoma Who Underwent Neoadjuvant Radiation Concurrent to Complementary and Alternative Medicine
  • Machine Learning Model to Guide Empirical Antimicrobial Therapy in Febrile Neutropenic Patients With Hematologic Malignancies
Show more Clinical Studies

Similar Articles

Keywords

  • Gastrojejunostomy
  • palliative surgery
  • gastric outlet obstruction
  • asymptomatic gastric outlet obstruction
  • pancreatic cancer
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire